NSC745885 (C007B-378982)

NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers.In VitroNSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the/ndensities of cultured cells when compared with untreated cells. The IC 50 of NSC745885 is 0.85 μM after 72 hours’ treatment. NSC745885 (0.5-4 μM; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner. NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM Incubation Time: 24, 48, or 72 hours Result: Decreases SAS cells growth as a time and dose-dependent manner. Apoptosis AnalysisCell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM Incubation Time: 24 hours Result: Decreases SAS cells growth as a time and dose-dependent manner. Western Blot AnalysisCell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM Incubation Time: 24 or 48 hours Result: Increased cleaved caspase-3 expression and decreased XIAP expression.In VivoNSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Eight-week-old NOD/SCID (NOD.CB17 Prkdc scid /J) mice Dosage: 2 mg/kg Administration: Intraperitoneal injection; 2 mg/kg; once daily; 10 days Result: Inhibited engrafted tumors growth in vivo.Form:Solid. Specification: ≥98.0% Molecular Formula: C14H6N2O2S Molecular Weight: 266.27 PubChem CID: 3835463 Isomeric SMILES: C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C4=NSN=C4C=C3